Novo Nordisk A/S $NVO Shares Acquired by Bank of New Hampshire

Key Points

• The Bank of New Hampshire increased its holdings in Novo Nordisk A/S by 39.8% during the 2nd quarter, bringing its ownership to 22,570 shares, valued at approximately $1.56 million.
• Novo Nordisk A/S reported earnings of $0.97 per share for the last quarter, surpassing analyst expectations of $0.93, while revenue was $11.69 billion.
• Research analysts have downgraded Novo Nordisk from a "buy" rating to a "neutral" or "hold," with the average target price now set at $81.00.

Bank of New Hampshire lifted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 39.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,570 shares of the company's stock after buying an additional 6,427 shares during the period. Bank of New Hampshire's holdings in Novo Nordisk A/S were worth $1,558,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Nuveen LLC acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $370,272,000. Two Sigma Investments LP purchased a new position in Novo Nordisk A/S during the fourth quarter worth approximately $158,657,000. Amundi boosted its stake in Novo Nordisk A/S by 49.1% during the first quarter. Amundi now owns 4,938,507 shares of the company's stock worth $331,576,000 after buying an additional 1,627,051 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Novo Nordisk A/S by 15,919.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company's stock valued at $72,523,000 after buying an additional 1,038,137 shares in the last quarter. Finally, Two Sigma Advisers LP increased its stake in shares of Novo Nordisk A/S by 649.0% in the 4th quarter. Two Sigma Advisers LP now owns 1,021,700 shares of the company's stock worth $87,887,000 after acquiring an additional 885,300 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 1.4%

NYSE:NVO opened at $55.62 on Tuesday. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $138.22. The firm has a market cap of $248.34 billion, a PE ratio of 15.28, a price-to-earnings-growth ratio of 2.08 and a beta of 0.66. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The stock has a fifty day moving average price of $57.69 and a 200 day moving average price of $65.92.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were paid a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is presently 22.53%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. UBS Group cut shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Zacks Research downgraded shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research note on Wednesday, August 20th. Barclays reiterated an "equal weight" rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Finally, TD Cowen reduced their price target on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a research report on Tuesday, August 19th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $81.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.